Mitchell Mcleod Pugh & Williams Inc. Has $958,000 Holdings in Pfizer Inc. (NYSE:PFE)

Mitchell Mcleod Pugh & Williams Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 5.1% in the fourth quarter, HoldingsChannel reports. The firm owned 33,261 shares of the biopharmaceutical company’s stock after selling 1,797 shares during the period. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Pfizer were worth $958,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Adage Capital Partners GP L.L.C. raised its stake in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new position in shares of Pfizer in the fourth quarter worth $255,000. Brookstone Capital Management boosted its holdings in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares during the period. ETF Store Inc. boosted its holdings in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. Finally, KLCM Advisors Inc. boosted its holdings in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Up 1.3 %

Pfizer stock traded up $0.34 during trading hours on Monday, hitting $25.74. 7,776,315 shares of the stock traded hands, compared to its average volume of 41,583,348. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $26.96 and its two-hundred day moving average price is $28.36. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a market cap of $145.75 billion, a PE ratio of 71.44, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.53%. Pfizer’s payout ratio is currently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.